Meeting
2018 ASCO Annual Meeting
A phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen.
Authors
Dingzhi Huang
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Dingzhi Huang , Ziping Wang , Xinmin Yu , Ying Cheng , Jie Wang , Yun Fan , Zhiyong Ma , Jianhua Shi , Yan Yu , Yi Hu , James Song , Fan Xia , Zhirong Shen , Yun Zhang , Yingying Xu , Carrie Condon , Fangniu Shi , Yunfei Zhou , Andrea Pirzkall , Caicun Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT03358875
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS3112)
DOI
10.1200/JCO.2018.36.15_suppl.TPS3112
Abstract #
TPS3112
Poster Bd #
320b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse
Poster
2023 ASCO Annual Meeting
ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.
First Author: Christos Chouaid
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok
Poster
2018 ASCO Annual Meeting
A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.
First Author: Shukui Qin